Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.67, $0.28 better than the analyst estimate of $0.39. Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE